Amedisys (NASDAQ:AMED - Get Free Report) issued its earnings results on Wednesday. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09), Zacks reports. The company had revenue of $598.05 million during the quarter, compared to analysts' expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%.
Amedisys Price Performance
NASDAQ:AMED traded up $0.32 during mid-day trading on Friday, hitting $92.00. 450,359 shares of the company's stock traded hands, compared to its average volume of 322,245. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market cap of $3.01 billion, a PE ratio of 36.51, a price-to-earnings-growth ratio of 1.78 and a beta of 0.73. The firm's 50 day simple moving average is $91.41 and its 200 day simple moving average is $93.18. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95.
Wall Street Analyst Weigh In
Separately, Stephens restated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a report on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Amedisys has a consensus rating of "Hold" and a consensus target price of $100.75.
View Our Latest Report on AMED
About Amedisys
(
Get Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Recommended Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
